Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients.
Launched in 2017, Tango has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
We have inverted the traditional discovery paradigm with our target discovery platform, where the discovery of novel targets and the associated patient selection strategy are integrated into a single experimental design. We leverage the principles of synthetic lethality to find novel dependencies in cancer cells and identify the relevant drug targets. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.